Â鶹ֱ²¥ & Lardner LLP represented Ora, a leading global full-service ophthalmic drug and device development firm, in its recapitalization by The Vistria Group, a middle-market private investment firm.
The Vistria Group’s investment will enable Ora to continue scaling its global operations and implementing advanced technologies to support ophthalmology innovators in developing the next generation of products. It also marks The Vistria Group’s commitment to further supporting cutting-edge therapies and advancing diversity in specialized clinical research.
Ora is the seventh company in The Vistria Group’s pharma services portfolio, underscoring the firm’s continued focus on life sciences.
The Â鶹ֱ²¥ team representing Ora was led by partner Susan Pravda and included partner Beth Felder and associates Paige Moscow and Grace Fucci, with assistance from partners Casey Knapp, Benjamin Dryden, John Palmer, Lynn Gandhi, of counsel Jeremy Abrams, senior counsel Kelsey O’Gorman, and additional support from partners Gabor Garai and Ethan Lenz.
